Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether quickly and intensively adjusting heart failure medications in women can improve outcomes after hospital stays for heart failure. The study aims to find out if this high-intensity treatment reduces death or hospital readmissions within one year, if women benefit as much as men from full-dose therapy, and if this approach is safe and manageable for women. This phase IV trial is sponsored by IRCCS Policlinico San Donato and involves multiple centers in Italy. Participants are randomly assigned to one of two groups a high-intensity care group that starts and increases all recommended heart failure drugs rapidly during hospitalization and early weeks after discharge, following the STRONG-HF protocol and a usual care group where medications are introduced and adjusted gradually according to doctors usual practice. The high-intensity group receives frequent clinical assessments and safety monitoring including vital signs, physical exams, and lab tests such as NT-proBNP and kidney function. Both groups have follow-up visits scheduled up to one year after randomization. Women in the study will attend regular visits at multiple time points over 12 months, completing quality-of-life questionnaires and undergoing safety checks. Researchers will measure a combined outcome of death, heart failure readmission, or worsening symptoms within a year. They will also assess medication optimization, side effects, biomarker changes, and overall quality of life. The study monitors participants closely to evaluate the safety, tolerance, and feasibility of rapid medication optimization in women with heart failure.